In a report released today, Kennen MacKay from RBC Capital reiterated a Hold rating on Puma Biotechnology (NYSEArca: PBYI), with a price target of $69. The company’s shares opened today at $54, close to its 52-week low of $45.50.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 19.2% and a 61.5% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Akebia Therapeutics, Spark Therapeutics, and Seattle Genetics.
Currently, the analyst consensus on Puma Biotechnology is a Moderate Buy with an average price target of $78.20, which is a 44.8% upside from current levels. In a report released yesterday, Cowen & Co. also reiterated a Hold rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $136.90 and a one-year low of $45.50. Currently, Puma Biotechnology has an average volume of 927.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.